Tonix Pharmaceuticals Holding Corp. (TNXP): Price and Financial Metrics


Tonix Pharmaceuticals Holding Corp. (TNXP): $0.62

0.03 (+4.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TNXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TNXP Stock Price Chart Interactive Chart >

Price chart for TNXP

TNXP Price/Volume Stats

Current price $0.62 52-week high $7.71
Prev. close $0.59 52-week low $0.29
Day low $0.59 Volume 931,593
Day high $0.64 Avg. volume 3,615,604
50-day MA $0.86 Dividend yield N/A
200-day MA $0.90 Market Cap 38.54M

Tonix Pharmaceuticals Holding Corp. (TNXP) Company Bio


Tonix Pharmaceuticals Holding Corp. is a pharmaceutical company that develops therapies for disorders of the central nervous system ("CNS"). The Company develops therapies for disorders that include fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD").


TNXP Latest News Stream


Event/Time News Detail
Loading, please wait...

TNXP Latest Social Stream


Loading social stream, please wait...

View Full TNXP Social Stream

Latest TNXP News From Around the Web

Below are the latest news stories about TONIX PHARMACEUTICALS HOLDING CORP that investors may wish to consider to help them evaluate TNXP as an investment opportunity.

Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine Congress

CHATHAM, N.J., March 27, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical and Farooq Nasar, Ph.D., Senior Principal Investigator, both of Tonix Pharmaceuticals, will deliver oral presentations at the World Vaccine Congress, which will be held in Washington D.C., April 3 - 6, 2023. Copies of the Company’s presentations will be available under

Yahoo | March 27, 2023

Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit

CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, delivered an oral presentation on March 23, 2023, at the Rare Disease Innovation and Partnership Summit being held as a hybrid event in Philadelphia, Pa. A copy of the presentation is available under the Scientific Presentations

Yahoo | March 23, 2023

Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in Fibromyalgia

CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will deliver an oral presentation and the Company will present a poster at the 5th International Congress on Controversies in Fibromyalgia being held March 30-31, 2023 at the Austria Trend Hotel Savoyen Vienna, Vienna, Austria. Copies of the Company’s presentati

Yahoo | March 23, 2023

Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit

CHATHAM, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the Virtual March Investor Summit on Wednesday, March 29, 2023, at 9:00 a.m. ET. Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator. A webcast of th

Yahoo | March 22, 2023

Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit

CHATHAM, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine of Tonix Pharmaceuticals, will deliver a presentation at the Rare Disease Innovation and Partnership Summit, which will be held as a hybrid event in Philadelphia, Pa., March 21 - March 23, 2023. A copy of the Company’s presentation will be available under

Yahoo | March 16, 2023

Read More 'TNXP' Stories Here

TNXP Price Returns

1-mo -11.43%
3-mo 59.06%
6-mo 16.06%
1-year -91.26%
3-year -97.15%
5-year -99.99%
YTD 59.06%
2022 -96.59%
2021 -47.01%
2020 -42.31%
2019 -94.68%
2018 -93.62%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7553 seconds.